A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score.

@article{Yamaguchi2015ASS,
  title={A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score.},
  author={Yuichiro Yamaguchi and Yujiro Hayashi and Yu Ishizuya and Ken Takeda and Yasutomo Nakai and Yasuyuki Arai and Masashi Nakayama and Ken-ichi Kakimoto and Kazuo Nishimura},
  journal={Japanese journal of clinical oncology},
  year={2015},
  volume={45 2},
  pages={
          197-201
        }
}
OBJECTIVE Japan Cancer of the Prostate Risk Assessment scores are reportedly useful for predicting progression-free survival after primary androgen deprivation therapy of prostate cancer patients. This study validated the risk assessment at a single institution. METHODS We studied 255 prostate cancer patients given primary androgen deprivation therapy. Progression-free survival, cause-specific survival and overall survival were analyzed according to Japan Cancer of the Prostate Risk… CONTINUE READING
3
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 14 REFERENCES

Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.

  • International journal of urology : official journal of the Japanese Urological Association
  • 2013
VIEW 1 EXCERPT

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

SmithMR, J Eastham, +3 authors N. Zinner
  • J Urol 2003;169:2008–12
  • 2008
VIEW 1 EXCERPT

Current status of endocrine therapy for prostate cancer in Japan-analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP

S Hinotsu, H Akaza, UsamiM
  • Jap J Clin Oncol 2007;37:775–81
  • 2007
VIEW 2 EXCERPTS

Clin - icopathological statistics on registered prostate cancer patients in Japan : 2000 report from the Japanese Urological Association

MA Eisenberger, BA Blumenstein, ED Crawford
  • Int J Urol
  • 2005

Similar Papers

Loading similar papers…